Viridian Therapeutics Inc

Viridian is a fast-follower executed with unusual discipline. It licensed a shelved oncology antibody (AVE-1642) from ImmunoGen, re-engineered the development thesis around thyroid eye disease, and beat a $1.9 billion incumbent on regimen convenience rather than on novel biology. FDA approval of Lumvoa (veligrotug-vvze) on 26 June 2026 — four days ahead of its PDUFA date, and with a label spanning both active and chronic TED — converted a decade of loss-making R&D into a commercial franchise overnight. The company now runs a rare-disease playbook it knows well: a concentrated 2,000-physician prescriber base, an in-house patient-services arm, and a follow-on subcutaneous autoinjector (elegrobart) intended to defend and expand the franchise from 2027. The strategic bet is that IGF-1R remains the dominant TED mechanism long enough for Viridian to build a two-product, self-funding rare-disease company before IL-6, FcRn, oral, and on-body-injector competitors arrive.

Viridian Therapeutics, Inc. is a Waltham, Massachusetts–headquartered, newly commercial-stage biotechnology company whose entire enterprise value rests on a single therapeutic mechanism — full antagonism of the insulin-like growth factor-1 receptor (IGF-1R) — applied to a single rare autoimmune indication, thyroid eye disease (TED), with adjacent optionality in neonatal Fc receptor (FcRn) inhibition and thyroid-stimulating hormone receptor (TSHR) blockade.

Headcount roughly tripled in two years. Management stated in a June 2026 interview that the organization had passed 400 employees, including approximately 100 newly hired sales representatives; a third-party workforce tracker put the figure at approximately 374 in July 2026. The precise mid-2026 headcount is not disclosed in an SEC filing and the two secondary figures differ.

What the company does. Viridian discovers, engineers, develops, and — as of June 2026 — commercializes monoclonal antibodies and engineered protein fragments for serious and rare autoimmune diseases. Its capabilities, as described in the FY2025 10-K, "span protein and antibody discovery and engineering, biologics manufacturing, nonclinical and clinical development, commercial planning, and commercialization."

The company's own characterization (FY2025 Form 10-K, Item 1). "We are a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases. We target therapeutic areas in which current treatments leave room for improvements in efficacy, safety, and/or dosing convenience." The filing describes a pipeline directed at three validated targets: IGF-1R for TED, FcRn for broad autoimmunity, and TSHR for TED and Graves' disease. Following the Lumvoa approval, the company's boilerplate description shifted to "autoimmune and rare diseases," dropping the earlier "serious and rare diseases" framing — a subtle repositioning toward the larger FcRn opportunity.

Independent characterization. Viridian is not a discovery-platform company despite its protein-engineering language. It is a mechanism-arbitrage company. Every clinical-stage asset targets a receptor whose therapeutic validity has already been established commercially by another party: IGF-1R by Amgen's Tepezza ($1.9 billion 2025 net sales), FcRn by argenx's Vyvgart (~$4.15 billion 2025 net sales), and TSHR by the well-characterized autoantibody biology of Graves' disease. The company's value creation comes from three levers applied to de-risked targets: (i) molecular re-engineering — full versus partial receptor antagonism, half-life extension via Xencor Xtend technology, Fc-fragment and albumin-binding-domain bispecific formats; (ii) regimen compression — five infusions instead of eight, 30–40 minutes instead of 60–90, every-4-week or every-8-week subcutaneous dosing instead of infusion-centre visits; and (iii) label breadth — running separate placebo-controlled Phase 3 studies in both active and chronic disease where the incumbent's label rests principally on active-disease data. This is a lower-risk, lower-differentiation model than novel-target discovery: it compresses scientific risk but raises commercial and pricing risk, because the fast follower must win on execution and access rather than on exclusivity.

Business and revenue model. As of the second quarter of 2026 the company has four current or prospective revenue lines:

Revenue mix is therefore transitional. FY2025 revenue of $70.8 million was 98.8% a one-time licensing payment. From FY2026 onward the mix should invert toward product sales, with royalty and milestone income as a secondary layer. Note the DRI arrangement is a liability, not revenue: Viridian owes DRI 7.5% of U.S. net sales up to $600 million annually, 0.8% between $600 million and $900 million, 0.25% between $900 million and $2 billion, and nothing above $2 billion. The 7.5% first-tier rate could step up to low double digits if elegrobart is not approved by a specified date — an important embedded penalty.

Value-chain position. Viridian occupies the discovery-through-commercialization span but outsources manufacturing entirely. It relies on third-party CDMOs — including a five-year non-exclusive Lumvoa supply agreement with WuXi Biologics disclosed in a May 2026 regulatory filing — and on Enable Injections' enFuse on-body system (a $15.0 million upfront paid in Q1 2023) and a commercially validated autoinjector for elegrobart. It has no owned manufacturing plant. Downstream, it sells through the specialty-distribution and buy-and-bill channel typical of infused rare-disease biologics, supported by ViridianCares, its in-house reimbursement and patient-support programme activated at approval.

Customer types and end-markets. The proximate customers are approximately 2,000 core prescribing physicians in the United States — predominantly oculoplastic surgeons, neuro-ophthalmologists, and endocrinologists — plus hospital outpatient departments and freestanding infusion centres. The economic buyers are commercial payers, Medicare Part B, and Medicaid. The end-market is a U.S. moderate-to-severe TED prevalent population the company estimates at approximately 190,000 patients, with comparable epidemiology in Europe. Ex-U.S. commercial rights are held by Viridian everywhere except Japan (Kissei) and Greater China (Zenas/Zai Lab).

Stated strategy — verbatim themes from the FY2025 Form 10-K

The company frames its mission as creating "new medicines for patients suffering from serious and rare diseases that are underserved by today's therapies," and articulates four strategic pillars:

1. "Identify, engineer, and develop potential best-in-class therapeutic proteins and antibodies that optimize patient care." The filing is explicit that this is a risk-reduction strategy: "Our approach leverages proven biology on clinically validated targets and our internal capabilities such as protein and antibody engineering to reduce development risk."
2. "Advance our lead programs in thyroid eye disease," comprising three sub-goals: seek marketing approval for veligrotug; "rapidly develop subcutaneous elegrobart as our next generation, potential best-in-class IGF-1R antibody"; and "commercially launch veligrotug, if approved, and prepare for the commercialization of elegrobart."
3. "Advance our portfolio of FcRn inhibitors with the potential to treat a broad array of autoimmune disorders."
4. "Leverage our differentiated strategy, strong capabilities, and track record of execution to continue discovering and developing novel, potential best-in class product candidates," including advancing the TSHR candidate to the clinic and monitoring "external opportunities for potential in-licensing."

Two strategic assertions deserve underlining because they carry commercial weight. First, on subcutaneous conversion: "There is precedent that subcutaneous therapies can quickly command substantial market share even when launching several years after an incumbent IV… market examples demonstrate that subcutaneous therapies have commanded market share even where such therapies have the same or worse dosing frequency than their IV counterparts." Second, on operating leverage: "Viridian anticipates that its current commercial and medical affairs infrastructure will support and accelerate a potential elegrobart launch with limited incremental investment."

Strategic initiatives announced in the last 24 months (September 2024 – September 2026)

Management's medium-term targets and guidance

Viridian does not issue revenue, expense or earnings guidance, and none of the reviewed filings contains a quantified financial target. The forward commitments management has made are operational and financial-capacity statements rather than guidance:

• Existing cash plus anticipated Lumvoa and elegrobart revenues are "expected to fund Viridian's current business plans through profitability" (Q2 2026).
• Elegrobart BLA submission in Q1 2027.
• TSHR IND in Q4 2026.
• VRDN-008 Phase 1 healthy-volunteer data in 2H 2026.
• VRDN-006 development plan to be communicated in 2026.
• Elegrobart launch to be supported by existing commercial infrastructure "with limited incremental investment."
• Commercial "critical mass" expected 6–9 months from launch (i.e., roughly Q1–Q2 2027), per the June 2026 approval call.

There is one approved product and four disclosed development programmes. Below, each is treated individually.

Lumvoa (veligrotug-vvze) — approved product

Pivotal evidence base. THRIVE (active TED, n=113; 75 drug / 38 placebo) delivered a 70% proptosis responder rate (64% placebo-adjusted, p<0.0001), 2.9 mm mean proptosis reduction, 63% diplopia responder rate, 54% complete diplopia resolution, 64% achieving CAS 0–1, and a 67% overall responder rate; placebo-adjusted hearing-impairment rate was 5.5%; 96% completed all doses; 53% responded on proptosis by week three. THRIVE-2 (chronic TED, n=188; 125 drug / 63 placebo; mean 69.8 months since onset) delivered a 56% PRR (48% placebo-adjusted, p<0.0001), 2.3 mm mean reduction, 56% diplopia responder rate (31% placebo-adjusted, p=0.0006), 32% complete diplopia resolution (18% placebo-adjusted, p=0.0152), and a 56% overall responder rate, with a 9.6% placebo-adjusted hearing-impairment rate. STRIVE (n=231, randomized 3:1 at 10 mg/kg versus a 3 mg/kg active control) supplied the 300-patient safety database. Fifty-two-week durability showed 70% of week-15 proptosis responders maintaining response.

Regulatory review nuances worth flagging. A published regulatory analysis of the approval package reports that FDA accepted the five-infusion 10 mg/kg regimen after additional dose-ranging work, identified a large discrepancy between clinical (exophthalmometry) and imaging-based estimates of chronic-disease durability, required revision of the reported anti-drug-antibody incidence because of assay limitations, and evaluated a severe immune thrombocytopenia case that remained confounded by underlying autoimmune disease. These are secondary-source characterizations of review documents; the company has not commented publicly on them, and readers should treat them as review-record observations rather than company disclosures.

Elegrobart (VRDN-003) — Phase 3 complete, BLA planned Q1 2027

Elegrobart is the single most consequential asset for the medium-term equity story and also the source of the year's largest disappointment. The market reaction to REVEAL-1 — a decline of more than 30% despite a met primary endpoint — reflected a comparison against veligrotug's own placebo-adjusted numbers rather than against placebo. A 54% Q4W PRR in active TED sits meaningfully below veligrotug's 70%, and the counter-intuitive inversion (Q8W outperforming Q4W on proptosis while Q4W outperformed on diplopia) complicates the dosing narrative and the commercial message.

VRDN-006 — FcRn inhibitor, Phase 1 complete

A highly selective Fc fragment inhibiting FcRn, designed for convenient subcutaneous self-administration. In head-to-head non-human primate studies it showed comparable in-vitro potency and comparable IgG lowering to efgartigimod, with a similar safety profile and no reduction in albumin or increase in LDL. Phase 1 healthy-volunteer data announced September 2025 showed class-consistent IgG reductions, albumin and LDL sparing, and general tolerability with no dose-limiting toxicities or serious adverse events. The company describes it as the only other known Fc fragment in development besides efgartigimod. IND submitted December 2024, cleared January 2025. A development plan — that is, an indication choice — has been promised "in 2026" for two consecutive years and had not been disclosed as of Q2 2026 reporting. Target customer, launch year and pricing model: not publicly disclosed.

VRDN-008 — bispecific half-life-extended FcRn inhibitor, Phase 1 ongoing

A bispecific comprising an Fc fragment plus an albumin-binding domain, designed to prolong IgG suppression. In a single high-dose head-to-head non-human primate study it demonstrated three times the half-life of efgartigimod, peak IgG reductions 20% deeper, and return to baseline IgG at 35 days versus 14 days for efgartigimod, while sparing albumin and LDL. IND submitted December 2025, cleared January 2026, Phase 1 healthy-volunteer trial ongoing with data guided to the second half of 2026 — a near-term catalyst.

TSHR programme — preclinical, IND planned Q4 2026

A half-life-extended monoclonal antibody designed to inhibit TSHR activation, formulated for subcutaneous autoinjector delivery with extended dosing intervals. Intended indications are TED and Graves' disease; the company notes Graves' affects more than 2 million people in the United States and is the leading cause of hyperthyroidism, with current options (antithyroid drugs, radioactive iodine, surgery) failing to address the underlying autoimmunity. No molecule name, no development-candidate designation and no preclinical data have been publicly released. IND targeted Q4 2026.

Legacy and discontinued

VRDN-002 (half-life-extended anti-IGF-1R for subcutaneous delivery) was deprioritized when VRDN-003 was selected as the lead subcutaneous candidate in December 2023. VRDN-004 and VRDN-005 were referenced as preclinical assets in 2022–2023 disclosures and no longer appear in the pipeline. The legacy miRagen microRNA assets (MRG-106/cobomarsen and others) were wound down after the 2020–2021 transition; no residual programme is disclosed.

Income statement

Gross profit is not a meaningful measure: the company recognized no cost of product revenue in any of the five years. Vendors that compute a "gross profit" line for VRDN (reported as -$53.9M in FY2021 through -$268.1M in FY2025) are simply subtracting R&D from revenue; that construction is not used here.

EBITDA is shown as approximate because depreciation and amortization is immaterial and is not broken out in the condensed statements. Gross property and equipment was $2.5 million at 31 December 2024 with $1.3 million of accumulated depreciation, implying annual D&A in the low hundreds of thousands of dollars. Treat EBITDA as effectively equal to operating income.

Margins (chartable):

Margin percentages are arithmetically valid but analytically meaningless for a company with de-minimis revenue; they are included for completeness and should not be charted alongside operating companies.

Revenue CAGR. FY2021–FY2025 total revenue CAGR is approximately +122% (from $2.96M to $70.85M), but this is an artefact of the single Kissei payment. Excluding the $70.0 million license payment, revenue declined at a compound annual rate of approximately -26.6% over the period as legacy collaboration activity wound down. Neither figure is predictive. The relevant growth base begins with Lumvoa product sales in Q3 2026.

Data discrepancy to note. For FY2022, the original Form 8-K Exhibit 99.1 dated 8 March 2023 reported net loss per share of -$4.05 on 32,087,293 weighted-average shares (implying the full $129.9 million loss was allocated to common). S&P Global Market Intelligence records show FY2022 net income to common of -$87.04 million and EPS of -$2.71, consistent with two-class-method allocation to the Series A and Series B convertible preferred. The FY2025 Form 10-K cover page carries a checked box indicating the financial statements "reflect the correction of an error to previously issued financial statements." The most likely explanation is a retrospective correction of the two-class EPS allocation, but Viridian has not publicly characterized the error, and the nature and magnitude of the correction are not publicly disclosed in the sources reviewed. Both figures are presented above so the discrepancy is visible.

Balance sheet

Notes to the balance sheet table: the company reports a highly condensed balance sheet in its earnings releases (cash, other assets, total assets, total liabilities, total equity), so a full current-asset and current-liability breakdown is not available from those releases. Property and equipment, net is disclosed only for FY2023 and FY2024 in the sources reviewed; the FY2021, FY2022 and FY2025 entries are shown as zero because the figure is not publicly disclosed in the sources reviewed, not because the balance is nil — readers should treat those three cells as unavailable. Goodwill and intangibles are genuinely nil: the October 2020 Viridian acquisition was expensed as acquired IPR&D of $69.9 million rather than capitalized. Accumulated deficit for FY2021 and FY2022 is likewise not publicly disclosed in the sources reviewed and is shown as zero; the FY2023 and FY2024 figures are from the FY2024 10-K details, and FY2025 is derived by adding the FY2025 net loss of $342.6 million to the FY2024 balance.

Post-period balance sheet (30 June 2026). Cash, cash equivalents and marketable securities $981.5 million; other receivable $75.0 million (the DRI approval milestone); other assets $40.7 million; total assets $1,097.2 million; total liabilities $435.1 million; total stockholders' equity $662.1 million. Total debt rose to $244.7 million following the May 2026 convertible issuance. Equity declined sequentially despite the equity raise because the $232.0 million of first-half losses exceeded the common-equity component of the financing.

Cash flow

Trailing-twelve-month operating cash flow to 30 June 2026 was -$333.3 million and free cash flow -$335.0 million, so the burn rate is still accelerating. Capital intensity is negligible — cumulative five-year capex of $3.05 million — which is the signature of a fully outsourced manufacturing model. The company has never paid a dividend and has never repurchased shares; the FY2025 10-K contains no dividend policy and none should be expected.

Ratios

Methodology and unavailable ratios: ROE and ROA for FY2022–FY2025 use average opening and closing balances; FY2021 uses year-end balances because the FY2020 balance sheet was not retrieved, so the FY2021 figures are not strictly comparable. ROIC, current ratio, net debt to EBITDA, interest coverage and cash conversion cycle are not meaningfully computable: invested capital returns are negative in every year, the condensed balance sheets do not split current from non-current items, EBITDA is negative in every year (making net-debt-to-EBITDA and interest coverage undefined), and there were no product sales or trade receivables and payables in any of the five years, making a cash conversion cycle undefined.

Commentary on trends, inflections and drivers

R&D. The dominant financial fact of the period is a six-fold increase in R&D spending, from $56.9 million in FY2021 to $338.9 million in FY2025. Three step-changes drive it. FY2022 (+77%) reflects CMC scale-up, preclinical costs and milestone/upfront payments ahead of THRIVE. FY2023 (+58%) reflects THRIVE and THRIVE-2 enrollment plus the $15.0 million Enable Injections upfront and VRDN-003 CMC work. FY2024–FY2025 (+49% then +42%) reflects the simultaneous conduct of five late-stage studies — THRIVE, THRIVE-2, STRIVE, REVEAL-1, REVEAL-2 — plus the safety and autoinjector studies and two FcRn Phase 1s. The inflection has now turned: Q2 2026 R&D fell to $71.6 million from $86.6 million a year earlier as veligrotug and elegrobart study costs rolled off, partially offset by TSHR investment and headcount.

SG&A. The FY2023 spike to $95.0 million is distorted by $31.0 million of one-time severance associated with the October 2023 leadership transition; underlying FY2023 SG&A was roughly $64.0 million. FY2024 of $61.1 million therefore represents flat-to-marginally-down underlying spend, not the 36% decline the headline suggests. The genuine inflection is FY2025 ($95.3 million, +56%) and, far more sharply, Q2 2026, where SG&A of $55.0 million was 2.7 times the $20.2 million of Q2 2025. Annualized, second-quarter SG&A implies a $220 million run-rate — an enormous commercial cost base for a product with no recorded sales yet. This is the launch bet in numerical form.

Net loss and financing. Net loss widened every year: -$79.4M, -$129.9M, -$237.7M, -$269.9M, -$342.6M. FY2025's loss would have been $412.6 million absent the Kissei payment. Other income peaked at $32.1 million of interest income in FY2024 on a large cash balance, fell to $20.8 million in FY2025 as rates and balances shifted, and turned negative in Q2 2026 (-$0.9 million) as convertible-note interest began accruing. That sign flip in other income is a small but real structural change: the company has stopped being a net beneficiary of its own cash pile.

Funding cadence. Cash rose in every single year despite widening burn, financed by a near-continuous sequence of raises: 2021 equity, 2022 equity, January 2024 (~$150 million), 2025 (multiple, including ~$251 million in November), October 2025 DRI royalty ($55 million upfront), and May 2026 ($394 million gross across converts, common and Series B preferred). Cumulative dilution is visible in the weighted-average share count, which grew from 11.9 million in FY2021 to 84.8 million in FY2025 and 107.9 million in Q2 2026 — roughly a nine-fold increase in five years. Net cash per share fell from $16.48 to $9.69 over the same period even as absolute cash quadrupled: the company bought its balance sheet with equity.

The forward statement that matters. Since Q2 2026 management has asserted that "existing cash and anticipated future commercial revenues from Lumvoa and elegrobart, if approved, are expected to fund Viridian's current business plans through profitability." This replaces the previous formulation, which was conditioned on DRI milestones. With $981.5 million of cash, a $75.0 million receivable, and a TTM burn of $333 million, the arithmetic works for roughly three years even on zero product revenue — but only if the burn does not grow, which the SG&A trajectory makes uncertain.

Management guidance

Viridian issues no financial guidance. Its forward commitments as of September 2026 are:

Consensus expectations

Seventeen to twenty-three analysts cover the stock; the consensus rating is Strong Buy or Buy with 85% positive recommendations and an average twelve-month target of approximately $35.4–$37.0, implying roughly 67–74% upside from $21.24. The target range spans $22 to $50. Yet the same consensus has cut FY2026 revenue expectations from $73.4 million to roughly $28.7 million over the course of the year and has removed break-even from the forecast horizon entirely, replacing a modelled 2028 profit of $40.4 million with a 2028 loss. Price targets have therefore been sustained by long-dated peak-sales assumptions rather than by near-term numbers — a configuration that historically resolves through target cuts if launch metrics disappoint, rather than through a gradual re-rating.

Bull case

1. The market is far larger than current revenue implies, and Viridian now has the better product for the larger half of it. Approximately 190,000 U.S. moderate-to-severe TED patients against a low-single-digit annual treatment rate, at $450,000 per course, means Tepezza's $1.9 billion reflects a fraction of demand. The untreated pool is disproportionately chronic — precisely where Lumvoa's THRIVE-2 label and elegrobart's REVEAL-2 dataset are strongest and where Tepezza's evidence is weakest. Winning the chronic segment does not require taking share from Amgen; it requires creating treated patients who do not exist today.
2. Execution has been demonstrated, repeatedly, under adverse conditions. Four pivotal trials, all positive on primary endpoint; two over-enrolled ahead of schedule; a BLA filed during a government shutdown; Priority Review granted; approval delivered four days early. In a sector where timeline slippage is the norm, this management team has met or beaten essentially every date it has set since October 2023 — with the single exception of the elegrobart BLA, which moved one quarter.
3. The company is funded through the decision points that matter. $981.5 million of cash, a $75.0 million receivable, up to $250 million of undrawn Hercules capacity, up to $315.0 million of remaining Kissei milestones, and $170 million of unearned DRI milestones. No debt maturity before 2032. Viridian can absorb a slow first year of launch, fund the elegrobart BLA and launch, take TSHR into the clinic and read out both FcRn assets without returning to the equity market — which, at $21 a share, is exactly the flexibility that creates option value.

Bear case

1. The convenience moat closes before elegrobart arrives. Satralizumab has a PDUFA of 15 October 2026 and would be the first at-home subcutaneous TED therapy. Amgen has positive Phase 3 data for subcutaneous teprotumumab with a 76.7% week-24 proptosis responder rate. Elegrobart's BLA will not even be submitted until Q1 2027, implying approval no earlier than late 2027 or 2028. By then Viridian's "first subcutaneous autoinjector" claim may be false and its "IV treatment of choice" positioning may be defending a shrinking format — with a 54% Q4W active-TED PRR that is below both its own IV product and Amgen's subcutaneous data.
2. Launch economics may not work at this cost base. Q2 2026 SG&A of $55.0 million annualizes to roughly $220 million against a product with no recorded sales, a consensus FY2026 revenue estimate cut to approximately $29 million, and a permanent 12–13% royalty leakage to ImmunoGen and DRI on first-tier U.S. sales. Layer on UnitedHealthcare's five-lifetime-infusion cap, which fixes maximum revenue per patient and eliminates retreatment, and a $450,000 parity price in a market moving from one brand to five within eighteen months. The sell-side consensus has already removed 2028 break-even from its models; management's "through profitability" claim and the analyst community's own numbers are not reconcilable.
3. The pipeline behind TED is late everywhere it competes. The FcRn assets are in Phase 1 against three approved products and a $4.15 billion incumbent projected to exceed $9 billion by 2030. The TSHR programme has no IND, no disclosed molecule and no preclinical data, and GenSci is already in Phase 1 with an anti-TSHR antibody. VRDN-006 has now had a development plan promised "in 2026" for two consecutive reporting years without delivery — a small tell about internal conviction. If TED does not compound, there is no second act within the forecast horizon, and the roughly $1.67 billion enterprise value is a pure TED valuation with no meaningful pipeline credit and none deserved yet.

Catalysts and monitorables for the next twelve months

Analyst verdict

Viridian has done the hard part. It took an abandoned oncology antibody, re-aimed it at a rare orbital disease, ran four clean pivotal trials, filed through a government shutdown, and got approved early with a broader label than the incumbent. That is a complete, well-executed drug-development cycle, and the team deserves credit for it. The problem is that the company reached the finish line just as the race changed.

The investment case rests on two beliefs. First, that TED is a vastly under-treated market where a better-labelled, shorter-course IV can create demand rather than merely take share. That belief is well supported: single-digit penetration of 190,000 U.S. patients is a real number, and chronic TED is genuinely underserved. Second, that elegrobart will convert that franchise into a durable subcutaneous business. That belief has weakened materially in 2026. REVEAL-1's 54% Q4W responder rate undershot veligrotug's own 70%, REVEAL-2's Q8W diplopia endpoints missed, and the BLA has slipped to Q1 2027 — into a window where satralizumab and possibly subcutaneous teprotumumab will already be establishing at-home treatment as normal.

The financial position is genuinely strong: $981.5 million of cash, no maturity before 2032, and multiple non-dilutive milestone streams. That buys time to be wrong once. But a $220 million annualized SG&A run-rate against a consensus that has cut FY2026 revenue to roughly $29 million and removed 2028 break-even entirely is not a small gap, and management's "funded through profitability" language should be treated as an aspiration rather than a forecast.

At $21.24, roughly 41% of the market capitalization is cash, and the enterprise is valued at about $1.67 billion — a modest price for a launched rare-disease franchise. The stock is not expensive. It is simply dependent, entirely, on the Q3 and Q4 2026 Lumvoa numbers. Everything else is currently opinion.

--